Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Nilotinib as Coadjuvant Treatment with Doxorubicin in Patients with Sarcomas: A Phase I Trial of the Spanish Group for Research on Sarcoma.

Alemany R, Moura DS, Redondo A, Martinez-Trufero J, Calabuig S, Saus C, Obrador-Hevia A, Ramos R, Villar VH, Valverde C, Vaz MA, Medina J, Felipe-Abrio I, Hindi N, Taron M, Martin-Broto J.

Clin Cancer Res. 2018 Nov 1;24(21):5239-5249. doi: 10.1158/1078-0432.CCR-18-0851. Epub 2018 Jul 23.

PMID:
30037815
2.

Wnt Signaling Inhibition Promotes Apoptosis in Sarcomas-Response.

Martinez-Font E, Vögler O, Alemany R, Obrador-Hevia A.

Mol Cancer Ther. 2017 Oct;16(10):2325. doi: 10.1158/1535-7163.MCT-17-0567. No abstract available.

3.

Disruption of TCF/β-Catenin Binding Impairs Wnt Signaling and Induces Apoptosis in Soft Tissue Sarcoma Cells.

Martinez-Font E, Felipe-Abrio I, Calabuig-Fariñas S, Ramos R, Terrasa J, Vögler O, Alemany R, Martín-Broto J, Obrador-Hevia A.

Mol Cancer Ther. 2017 Jun;16(6):1166-1176. doi: 10.1158/1535-7163.MCT-16-0585. Epub 2017 Mar 14.

4.

Efficacy of the GemOx-R regimen leads to the identification of Oxaliplatin as a highly effective drug against Mantle Cell Lymphoma.

Obrador-Hevia A, Serra-Sitjar M, Rodríguez J, Belayachi L, Bento L, García-Recio M, Sánchez JM, Villalonga P, Gutiérrez A, Fernández de Mattos S.

Br J Haematol. 2016 Sep;174(6):899-910. doi: 10.1111/bjh.14141. Epub 2016 May 25.

PMID:
27220900
5.

RG7112, a small-molecule inhibitor of MDM2, enhances trabectedin response in soft tissue sarcomas.

Obrador-Hevia A, Martinez-Font E, Felipe-Abrio I, Calabuig-Fariñas S, Serra-Sitjar M, López-Guerrero JA, Ramos R, Alemany R, Martín-Broto J.

Cancer Invest. 2015;33(9):440-50. doi: 10.3109/07357907.2015.1064534. Epub 2015 Aug 17.

PMID:
26288114
6.

RG7112, a Small-Molecule Inhibitor of MDM2, Enhances Trabectedin Response in Soft Tissue Sarcomas.

Obrador-Hevia A, Martinez-Font E, Felipe-Abrio I, Calabuig-Fariñas S, Serra-Sitjar M, López-Guerrero JA, Ramos R, Alemany R, Martín-Broto J.

Cancer Invest. 2015 Aug 17. [Epub ahead of print]

PMID:
26279182
7.

Oleanolic and maslinic acid sensitize soft tissue sarcoma cells to doxorubicin by inhibiting the multidrug resistance protein MRP-1, but not P-glycoprotein.

Villar VH, Vögler O, Barceló F, Gómez-Florit M, Martínez-Serra J, Obrador-Hevia A, Martín-Broto J, Ruiz-Gutiérrez V, Alemany R.

J Nutr Biochem. 2014 Apr;25(4):429-38. doi: 10.1016/j.jnutbio.2013.12.003. Epub 2013 Dec 31.

PMID:
24491315
8.

Cyclosquaramides as kinase inhibitors with anticancer activity.

Villalonga P, Fernández de Mattos S, Ramis G, Obrador-Hevia A, Sampedro A, Rotger C, Costa A.

ChemMedChem. 2012 Aug;7(8):1472-80. doi: 10.1002/cmdc.201200157. Epub 2012 Jul 9.

PMID:
22777958
9.

The tumour suppressor FOXO3 is a key regulator of mantle cell lymphoma proliferation and survival.

Obrador-Hevia A, Serra-Sitjar M, Rodríguez J, Villalonga P, Fernández de Mattos S.

Br J Haematol. 2012 Feb;156(3):334-45. doi: 10.1111/j.1365-2141.2011.08951.x. Epub 2011 Nov 23.

PMID:
22107151
10.

Therapeutic concepts in mantle cell lymphoma.

Rodriguez J, Gutierrez A, Obrador-Hevia A, Fernandez de Mattos S, Cabanillas F.

Eur J Haematol. 2010 Nov;85(5):371-86. doi: 10.1111/j.1600-0609.2010.01515.x. Review.

PMID:
20727006
11.

Oncogenic KRAS is not necessary for Wnt signalling activation in APC-associated FAP adenomas.

Obrador-Hevia A, Chin SF, González S, Rees J, Vilardell F, Greenson JK, Cordero D, Moreno V, Caldas C, Capellá G.

J Pathol. 2010 May;221(1):57-67. doi: 10.1002/path.2685.

12.

Molecular biology of mantle cell lymphoma: from profiling studies to new therapeutic strategies.

Obrador-Hevia A, Fernández de Mattos S, Villalonga P, Rodríguez J.

Blood Rev. 2009 Sep;23(5):205-16. doi: 10.1016/j.blre.2009.03.001. Epub 2009 Apr 10. Review.

PMID:
19362399
13.

Jagged1 is the pathological link between Wnt and Notch pathways in colorectal cancer.

Rodilla V, Villanueva A, Obrador-Hevia A, Robert-Moreno A, Fernández-Majada V, Grilli A, López-Bigas N, Bellora N, Albà MM, Torres F, Duñach M, Sanjuan X, Gonzalez S, Gridley T, Capella G, Bigas A, Espinosa L.

Proc Natl Acad Sci U S A. 2009 Apr 14;106(15):6315-20. doi: 10.1073/pnas.0813221106. Epub 2009 Mar 26.

14.

Functional characterization of the novel APC N1026S variant associated with attenuated familial adenomatous polyposis.

Menéndez M, González S, Obrador-Hevia A, Domínguez A, Pujol MJ, Valls J, Canela N, Blanco I, Torres A, Pineda-Lucena A, Moreno V, Bachs O, Capellá G.

Gastroenterology. 2008 Jan;134(1):56-64. doi: 10.1053/j.gastro.2007.10.009. Epub 2007 Oct 10.

PMID:
18166348
15.

APC inactivation associates with abnormal mitosis completion and concomitant BUB1B/MAD2L1 up-regulation.

Abal M, Obrador-Hevia A, Janssen KP, Casadome L, Menendez M, Carpentier S, Barillot E, Wagner M, Ansorge W, Moeslein G, Fsihi H, Bezrookove V, Reventos J, Louvard D, Capella G, Robine S.

Gastroenterology. 2007 Jun;132(7):2448-58. Epub 2007 Mar 19.

PMID:
17570218

Supplemental Content

Loading ...
Support Center